SecBot SecBot
PTAB-TRIAL ·Filed Nov 10, 2026

SPRB

SPRUCE BIOSCIENCES, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed6d 10h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB institution decision (instituted)
Actionable Insight • Neutral

Monitor the upcoming final written decision, expected within roughly 12 months. If the patent is upheld, it strengthens Spruce's exclusivity for the treatment method; if claims are cancelled, it could expose the company to competition from Neurocrine or others.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$46.67
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.00%
T+1 · $46.20
Vs SPY
−2.32%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $46.67entry
  2. T+1 · 6d ago −1.00%α −2.32% · $46.20
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

Executive Summary

The PTAB granted institution of post-grant review (PGR2026-00060) on Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. This is an interlocutory decision that opens a trial; no claims have been cancelled yet.

PTAB Trial Details

Proceeding
PGR2026-00060
Proceeding Type
PGR (post-grant review)
Decision
Trial instituted
Company Role
Patent owner
Outcome for Patent Owner
Pending (trial to come)
Patent
U.S. 12,569,490
Patent Covers
methods for treating testicular and ovarian adrenal rest tumors
Challenged Claims
not stated
Next Step
final written decision due within approximately one year

Key Facts

  • PTAB instituted PGR2026-00060 on Spruce Biosciences' U.S. Patent 12,569,490
  • Patent covers methods for treating testicular and ovarian adrenal rest tumors
  • Petitioner is Neurocrine Biosciences, Inc.
  • Decision is interlocutory, no claims have been cancelled
  • Trial will proceed with a final written decision due within approximately one year

Financial Impact

Patent protects a treatment method for adrenal rest tumors; no revenue or market exposure figures stated in the decision

Risk Factors

  • Institution granted means the patent faces a substantive challenge; a final decision finding claims unpatentable would remove patent protection
  • No financial data in the decision to quantify revenue at risk
  • Appeal to the Federal Circuit is possible after a final written decision

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2026-00060-ins-SPRB

US Market Status

Market Closed · Opens in 9h 28m

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 10, 2026